#United States #Chicago #Antengene #KEYTRUDA #ATG-037

Antengene's Latest Clinical Trials: A Breakthrough in Cancer Treatment

Antengene Corporation Limited, a leading global biopharmaceutical innovator, recently announced significant findings from two clinical studies focused on treating checkpoint inhibitor-resistant solid tumors. These results are set to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 to June 3, 2025, in Chicago, IL.

Overview of the Trials

Antengene's commitment to developing cutting-edge cancer treatments is evident in their latest clinical trials involving ATG-037, an oral small molecule CD73 inhibitor used in conjunction with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and ATG-008, an oral dual mTORC1/2 inhibitor, combined with toripalimab. These trials focus on patients with solid tumors resistant to current checkpoint inhibitors, a pressing issue in oncology management.

Key Findings from the Trials

STAMINA-01 Trial

The STAMINA-01 trial showcased impressive results among melanoma patients who have shown resistance to checkpoint inhibitors. Notably, ATG-037 demonstrated an overall response rate (ORR) of 36.4% and a disease control rate (DCR) of 100%, with one patient maintaining a partial response for over two years without significant safety concerns.

In similar findings for non-small cell lung cancer (NSCLC), the combination therapy led to an ORR of 22% and a DCR of 67%. A total of 43 patients were enrolled, with promising outcomes indicating that ATG-037 has the potential to be a pioneering treatment for various CPI-resistant cancers.

The side effects associated with this therapy appeared manageable, with treatment-related adverse events reported in 56% of patients receiving ATG-037 alone and 61% when combined with pembrolizumab - mainly experiencing grade 1 or 2 side effects.

TORCH-2 Trial

Shifting focus to cervical cancer, the TORCH-2 trial evaluated the efficacy of ATG-008 combined with toripalimab. This trial revealed an ORR of 22.2% and a DCR of 85.2% among CPI-resistant patients. Within this group, responses in both PD-L1 positive and negative individuals were noted, showcasing a median progression-free survival (PFS) of 4.2 months and an overall survival (OS) of 21.4 months.

The results have underscored the viability of ATG-008 as a novel therapeutic option for patients with advanced cervical cancer who previously faced treatment challenges. However, the safety profile warranted attention as well, with 73.3% of participants reporting grade 3 or higher adverse events, indicating the need for careful monitoring in clinical settings.

Antengene's Commitment to Innovation

Antengene's advancements in developing these novel therapies signify the company's dedication to improving treatment options for patients battling hard-to-treat cancers. Both ATG-037 and ATG-008 exemplify the company’s innovative approach to overcoming the limitations presented by current treatment modalities.

As the ASCO 2025 meeting approaches, the anticipation surrounding Antengene’s findings highlights the potential shifts in cancer treatment paradigms, particularly for patients with limited options due to resistance to established therapies. By presenting these significant data, Antengene not only aids in expanding the horizons of cancer treatment but also reinforces the importance of continued research and investment in novel therapeutics.

Antengene continues to lead the way in transforming cancer care, embodying its vision of 'Treating Patients Beyond Borders' by making a global impact in oncology.

Conclusion

As the global community waits for further developments, Antengene's presentation at ASCO 2025 heralds a bright future for innovative therapies in the fight against cancer. With promising findings and a commitment to improving patient outcomes, the company is undoubtedly setting the foundation for the next generation of cancer treatment options.